Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis - GBI Research Reports

Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis

Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis - GBI Research Reports
Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis
Published Oct 01, 2010
169 pages — Published Oct 01, 2010
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research's report, 'Musculoskeletal Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First-in-class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis', provides in-depth analysis of unmet needs, drivers and barriers that impact the global musculoskeletal disorders market. The report analyzes the markets for musculoskeletal disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The scope of this report includes:
- Annualized market data for the musculoskeletal disorders therapeutics market from 2001 to 2009, with forecasts to 2016.
- Data and analysis on the musculoskeletal disorders therapeutics market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain, and Japan.
- Market Data on geographical landscape and therapeutic landscape including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Key drivers and restraints that have created significant impact on the market.
- Competitive landscape of the global musculoskeletal disorders therapeutics market including top companies benchmarking. The key companies studied in this report are Roche/Genentech, Novartis, Amgen, Merck/Schering-Plough, Pfizer/Wyeth, Bristol-Myers Squibb and Eli Lilly, Procter and Gamble, Johnson and Johnson, Abbott Laboratories and Boehringer Ingelheim
- Key M&A activities, Licensing Agreements, that have taken place between 2008 and 2009 in the musculoskeletal disorders therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to :
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety.

  
Source:
Document ID
GBIHC032MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents38
1.1 List of Tables53
1.2 List of Figures83
2 Global Musculoskeletal Disorders Therapeutics Market: Introduction112
2.1 GBI Research Report Guidance121
3 Global Musculoskeletal Disorders Therapeutics Market: Market Overview139
3.1 Introduction131
3.2 Revenue Forecasts for the Global Musculoskeletal Disorders Therapeutics Market141
3.2.1 Revenue141
3.2.2 Annual Cost of Treatment (ACT)151
3.2.3 Treatment Usage Patterns161
3.2.3.1 Diseased Population171
3.2.3.2 Treatment Seeking Population181
3.2.3.3 Diagnosis Population191
3.2.3.4 Prescription Population201
3.3 Generics in Musculoskeletal Disorders Therapeutics Market211
4 Global Musculoskeletal Disorders Therapeutics Market: Geographical Landscape2231
4.1 Revenue Analysis By Geography 222
4.2 The US241
4.2.1 Revenue242
4.2.2 Annual Cost of Treatment 262
4.2.3 Treatment Usage Patterns282
4.2.3.1 Diseased Population301
4.2.3.2 Treatment Seeking Population311
4.2.3.3 Diagnosis Population321
4.2.3.4 Prescription Population331
4.3 Top Five EU Countries341
4.3.1 Revenue342
4.3.2 Annual Cost of Treatment 362
4.3.3 Treatment Usage Patterns382
4.3.3.1 Diseased Population401
4.3.3.2 Treatment Seeking Population411
4.3.3.3 Diagnosis Population421
4.3.3.4 Prescription Population431
4.4 Japan441
4.4.1 Revenue442
4.4.2 Annual Cost of Treatment461
4.4.3 Treatment Usage Patterns472
4.4.3.1 Diseased Population491
4.4.3.2 Treatment Seeking Population501
4.4.3.3 Diagnosis Population511
4.4.3.4 Prescription Population521
5 Global Musculoskeletal Disorders Therapeutics Market: Therapeutic Landscape 5349
5.1 Osteoporosis Therapeutics Market531
5.1.1 Introduction531
5.1.2 Revenue532
5.1.3 Annual Cost of Treatment552
5.1.4 Treatment Usage Patterns573
5.1.4.1 Diseased Population601
5.1.4.2 Treatment Seeking Population611
5.1.4.3 Diagnosis Population621
5.1.4.4 Prescription Population631
5.1.5 Drivers and Barriers for the Osteoporosis Therapeutics Market641
5.1.5.1 Drivers for the Osteoporosis Therapeutics Market 651
5.1.5.2 Barriers for the Osteoporosis Therapeutics Market 651
5.1.6 Opportunity and Unmet Need651
5.2 Osteoarthritis Therapeutics Market661
5.2.1 Introduction661
Revenue662
5.2.3 Annual Cost of Treatment681
5.2.4 Treatment Usage Patterns693
5.2.4.1 Diseased Population721
5.2.4.2 Treatment Seeking Population731
5.2.4.3 Diagnosis Population741
5.2.4.4 Prescription Population751
5.2.5 Drivers and Barriers for the Osteoarthritis Therapeutics Market761
5.2.5.1 Drivers for the Osteoarthritis Therapeutics Market 771
5.2.5.2 Barriers for the Osteoarthritis Therapeutics Market 771
5.2.6 Opportunity and Unmet Need771
5.3 Rheumatoid Arthritis Therapeutics Market781
5.3.1 Introduction781
Revenue782
5.3.3 Annual Cost of Treatment802
5.3.4 Treatment Usage Patterns822
5.3.4.1 Diseased Population841
5.3.4.2 Treatment Seeking Population851
5.3.4.3 Diagnosis Population861
5.3.4.4 Prescription Population871
5.3.5 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market 881
5.3.5.1 Drivers for the Rheumatoid Arthritis Therapeutics Market 881
5.3.5.2 Barriers for the Rheumatoid Arthritis Therapeutics Market 881
5.3.6 Unmet Need for Rheumatoid Arthritis Therapeutics Market 891
5.4 Muscular Dystrophy Therapeutics Market901
5.4.1 Introduction901
5.4.2 Revenue902
5.4.3 Annual Cost of Treatment921
5.4.4 Treatment Usage Patterns933
5.4.4.1 Diseased Population961
5.4.4.2 Treatment Seeking Population971
5.4.4.3 Diagnosis Population981
5.4.4.4 Prescription Population991
5.4.5 Drivers and Barriers for the Muscular Dystrophy Therapeutics Market 1001
5.4.5.1 Drivers for the Muscular Dystrophy Therapeutics Market 1001
5.4.5.2 Barriers for the Muscular Dystrophy Therapeutics Market 1011
5.4.6 Unmet Need for Muscular Dystrophy Therapeutics Market 1011
6 Global Musculoskeletal Disorders Therapeutics Market: Pipeline Analysis10232
Introduction1021
6.1.1 Research and Development Pipeline Osteoarthritis1036
6.1.2 Research and Development Pipeline Osteoporosis1099
6.1.3 Research and Development Pipeline Rheumatoid Arthritis11811
6.1.4 Research and Development Pipeline Muscular Dystrophy1293
6.2 Profiles of Promising Drugs in the Musculoskeletal Disorders Therapeutics Market1321
Catena/Sovrima (Idebenone) 1321
6.2.1.1 Overview 1321
6.2.1.2 Efficacy 1321
6.2.1.3 Safety 1321
6.2.1.4 Clinical Study Details 1321
6.2.2 IPlex(TM) (Mecasermin Rinfabate) 1321
6.2.2.1 Overview 1321
6.2.2.2 Efficacy 1321
6.2.2.3 Safety 1321
6.2.2.4 Clinical Study Details 1321
6.2.3 CG5503 (Tapentadol ER)1331
6.2.3.1 Overview 1331
6.2.3.2 Efficacy 1331
6.2.3.3 Safety 1331
6.2.3.4 Clinical Study Details 1331
7 Global Musculoskeletal Disorders Therapeutics Market: Competitive Landscape13418
7.1 Evolving competitive landscape1341
7.1.1 Major Players1351
7.2 Market Share Analysis1361
7.3 Competitive Profiling1371
7.3.1 Novartis AG1371
7.3.1.1 Company Overview 1371
7.3.1.2 Business Description 1371
7.3.1.3 Marketed Drugs1381
7.3.2 Pfizer1381
7.3.2.1 Company Overview 1381
7.3.2.2 Business Description 1391
7.3.2.3 Marketed Drugs1391
7.3.3 Hoffmann-La Roche Ltd.1391
7.3.3.1 Company Overview 1391
7.3.3.2 Business Description 1401
7.3.3.3 Marketed Drugs1401
7.3.4 Merck &Co., Inc1411
7.3.4.1 Company Overview 1411
7.3.4.2 Business Description 1411
7.3.4.3 Marketed Drugs1412
7.3.5 Eli Lilly and Company1431
7.3.5.1 Company Overview 1431
7.3.5.2 Business Description 1431
7.3.5.3 Marketed Drugs1432
7.3.6 Abbott Laboratories1451
7.3.6.1 Company Overview 1451
7.3.6.2 Business Description 1451
7.3.6.3 Marketed Drugs1451
7.3.7 Johnson &Johnson1461
7.3.7.1 Company Overview 1461
7.3.7.2 Business Description 1461
7.3.7.3 Marketed Drugs1471
7.3.8 Amgen Inc.1471
7.3.8.1 Company Overview 1471
7.3.8.2 Business Description 1471
7.3.8.3 Marketed Drugs1481
7.3.9 Procter &Gamble Company1491
7.3.9.1 Company Overview 1491
7.3.9.2 Business Description 1491
7.3.9.3 Marketed Drugs1491
7.3.10 Bristol-Myers Squibb Company1501
7.3.10.1 Company Overview 1501
7.3.10.2 Business Description 1501
7.3.10.3 Marketed Drugs1502
8 Global Musculoskeletal Disorders Therapeutics Market: M&A Landscape15211
8.1 Overview1521
8.1.1 Pfizer Acquires Wyeth1531
8.1.2 Cephalon Acquires Arana Therapeutics1531
8.1.3 Aspen Pharmacare Acquires Sigma Pharmaceuticals1531
8.2 R&D Licensing Agreements 1531
8.2.1 Deals by Phase1531
Deals by Geography1541
8.2.3 Deals by Value ($)1551
8.2.4 Preclinical1561
8.2.4.1 RDEA1191561
8.2.4.2 BGC 9451561
8.2.4.3 Astex FGFr Inhibitor Program1561
8.2.4.4 DX-22401571
8.2.5 Phase I1571
8.2.5.1 BTT-1023 1571
8.2.5.2 PG1101571
8.2.5.3 Sodium Pentosan Polysulfate 1581
8.2.6 Phase II1581
8.2.6.1 ALD5181581
8.2.7 Phase III1591
8.2.7.1 Calcitonin1591
8.2.8 Approved1601
8.2.8.1 Pennsaid and Pennsaid Plus1611
8.2.8.2 Voltaren Gel1611
8.2.8.3 DW-13501611
8.2.9 Marketed Drugs1621
8.2.9.1 Calcitonin1621
8.2.9.2 Fosteum1621
9 Global Musculoskeletal Disorders Therapeutics Market: Appendix1637
9.1 Market Definitions1631
9.2 Abbreviations1632
9.3 Research Methodology1655
9.3.1 Coverage1651
9.3.2 Secondary Research1651
9.3.3 Primary Research1661
9.3.4 Forecasts1661
9.3.4.1 Epidemiology-based Forecasting1663
9.3.5 Expert Panel Validation1691
9.4 Contact Us1691
9.5 Disclaimer1691
9.6 Sources1691

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis" Oct 01, 2010. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Musculoskeletal-Disorders-Therapeutics-to-2016-Introduction-of-Monoclonal-Antibodies-with-First-in-class-Mechanism-of-Action-to-Increase-Treatment-Options-in-Osteoporosis-and-Rheumatoid-Arthritis-2115-91>
  
APA:
GBI Research Reports. (2010). Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis Oct 01, 2010. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Musculoskeletal-Disorders-Therapeutics-to-2016-Introduction-of-Monoclonal-Antibodies-with-First-in-class-Mechanism-of-Action-to-Increase-Treatment-Options-in-Osteoporosis-and-Rheumatoid-Arthritis-2115-91>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.